Skip to main content
Top
Published in: Clinical Rheumatology 6/2004

01-12-2004 | Original Article

Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies

Authors: Insoo Kang, Robyn Siperstein, Tim Quan, Mary Lou Breitenstein

Published in: Clinical Rheumatology | Issue 6/2004

Login to get access

Abstract

Monovariate and multivariate analyses including logistic regression were performed to determine associations among predicting variables [age, gender, immunofluorescence pattern, and anti-nuclear antibody (ANA) titer] and anti-extractable nuclear antigen (ENA) and -dsDNA antibodies (Abs) in 1089 patients with positive fluorescent ANA (FANA) test results. Samples with high titer ANAs had an increased frequency of anti-ENA and -dsDNA Abs. The receiver operating (ROC) curves of the ANA titer for anti-ENA Abs had a larger under the curve area compared to the ROC curve for anti-dsDNA Abs, indicating that ANA titer is better for predicting anti-ENA Abs than anti-dsDNA Abs. There was no relation noticed between immunofluorescence patterns and anti-ENA and -dsDNA Abs except an increased frequency of anti-dsDNA Abs found in samples with a homogeneous pattern. Probability calculations on the basis of the ANA pattern and the titer showed that samples with low titer ANAs (1:160 or less) had low probabilities for anti-ENA Abs (0.002–0.009) regardless of immunofluorescence patterns. However, samples with a homogeneous pattern at any titers including low titers had high probabilities for anti-dsDNA Abs. A decreased frequency of anti-dsDNA Abs as measured by Crithidia assay was noticed in samples from patients aged 50 or older. In contrast, no association was noticed between age and anti-ENA Abs. There was no female preponderance found in the presence of anti-ENA and -dsDNA Abs. In conclusion, our study shows that the ANA titer but not the immunofluorescence pattern is useful in predicting anti-ENA Abs. In contrast, both the ANA titer and the immunofluorescence pattern help in predicting anti-dsDNA Abs. Samples with low titer ANAs (1:160 or less) may not need a further test for anti-ENA Abs unless an ANA-associated disease is highly suspected. However, a test for anti-dsDNA Abs should be considered in samples with a homogeneous pattern at any titer including low titers.
Literature
1.
go back to reference Brown BW (1980) Prediction analyses for binary data. In: Miller RG, Efron B, Brown BW, Moses LE (eds) Biostatistics casebook. John Wiley and Sons, New York Brown BW (1980) Prediction analyses for binary data. In: Miller RG, Efron B, Brown BW, Moses LE (eds) Biostatistics casebook. John Wiley and Sons, New York
2.
go back to reference Craig WY, Ledue TB, Johnson AM, Ritchie RF (1999) The distribution of antinuclear antibody titers in “normal” children and adults. J Rheumatol 26:914–919PubMed Craig WY, Ledue TB, Johnson AM, Ritchie RF (1999) The distribution of antinuclear antibody titers in “normal” children and adults. J Rheumatol 26:914–919PubMed
3.
go back to reference de Vlam K, De Keyser F, Verbruggen G, et al. (1993) Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 11:393–397PubMed de Vlam K, De Keyser F, Verbruggen G, et al. (1993) Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 11:393–397PubMed
4.
go back to reference Homburger HA (1995) Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 70:183–184PubMed Homburger HA (1995) Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 70:183–184PubMed
5.
go back to reference Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124:71–81PubMed Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124:71–81PubMed
6.
go back to reference Malleson PN, Sailer M, Mackinnon MJ (1997) Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 77:299–304PubMed Malleson PN, Sailer M, Mackinnon MJ (1997) Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 77:299–304PubMed
7.
go back to reference Peene I, Meheus L, Veys EM, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60:1131–1136CrossRefPubMed Peene I, Meheus L, Veys EM, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60:1131–1136CrossRefPubMed
8.
go back to reference Peng SL, Hardin JA, Craft J (1997) Antinuclear antibodies. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) Text book of rheumatology. WB Saunders, Philadelphia, pp 250–266 Peng SL, Hardin JA, Craft J (1997) Antinuclear antibodies. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) Text book of rheumatology. WB Saunders, Philadelphia, pp 250–266
9.
go back to reference Vaile JH, Dyke L, Kherani R, Johnston C, Higgins T, Russell AS (2000) Is high titre ANA specific for connective tissue disease? Clin Exp Rheumatol 18:433–438PubMed Vaile JH, Dyke L, Kherani R, Johnston C, Higgins T, Russell AS (2000) Is high titre ANA specific for connective tissue disease? Clin Exp Rheumatol 18:433–438PubMed
Metadata
Title
Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies
Authors
Insoo Kang
Robyn Siperstein
Tim Quan
Mary Lou Breitenstein
Publication date
01-12-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0937-0

Other articles of this Issue 6/2004

Clinical Rheumatology 6/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.